Document:

Exhibit
4.1

 

EXECUTION
VERSION

 

 

SECURITIES
PURCHASE AGREEMENT

 

This
Securities Purchase Agreement (this “Agreement”), dated
as of September 25, 2022, is made by and among Anebulo Pharmaceuticals, Inc., a
Delaware corporation (the “Company”), and the Purchasers listed on Exhibit A hereto, together with their
permitted transferees (each, a “Purchaser” and collectively, the “Purchasers”).

 

RECITALS:

 

A.
The Company and the Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act.

 

B.
The Purchasers desire to purchase and the Company desires to sell, upon the terms and conditions stated in this Agreement, shares
of Common Stock (the “Common Shares”), Common Warrants, and Pre-Funded Warrants as more fully described in
this Agreement.

 

C.
The capitalized terms used herein and not otherwise defined have the meanings given them in Article 7.

 

AGREEMENT

 

In
consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Company and the Purchasers (severally and not jointly) hereby agree as follows:

 

Article
1

PURCHASE AND SALE OF SECURITIES

 

1.1
Closing. 

 

(a)
Purchase and Sale of Securities. At the closing of the transaction contemplated by this Agreement (the “Closing”),
the Company will sell and issue to each Purchaser, and each Purchaser will, severally and not jointly, purchase from the Company, (A)
the number of Common Shares equal to (x) the dollar amount set forth opposite such Purchaser’s name on Exhibit A hereto
under the heading “Common Share Subscription Amount” (“Common Share Subscription Amount”) divided
by (y) the Market Price, rounded down to the nearest whole share; provided, however, in the event the number of Common Shares
resulting from the foregoing calculation would result in such Purchaser, together with its Attribution Parties, beneficially owning in
excess of the Beneficial Ownership Limitation of the outstanding Common Stock immediately after the Closing, then (i) the number of Common
Shares otherwise issuable to such Purchaser at the Closing will be reduced by the number (such number, the “Overage Number”)
of Common Shares that would result in such Purchaser beneficially owning, together with its Attribution Parties, no more than the Beneficial
Ownership Limitation of the outstanding Common Stock immediately after the Closing, (ii) the Company will issue to such Purchaser at
the Closing a Pre-Funded Warrant to purchase the number of whole Pre-Funded Warrant Shares (in the aggregate and without regard to any
exercise limitations) equal to the Overage Number, and (iii) the dollar amount set forth opposite such Purchaser’s name on Exhibit
A hereto under the heading “Common Share Subscription Amount” shall be reduced by the amount equal to the number of Pre-Funded
Warrant Shares underlying the Pre-Funded Warrant multiplied by $0.001, and (B) a Common Warrant in the form attached hereto as Exhibit
C exercisable for a number of shares of Common Stock equal to the number of Common Shares purchased by the Purchaser at the Closing
plus, if applicable, the number of Pre-Funded Warrant Shares issuable upon exercise of the Pre-Funded Warrants purchased by the Purchaser
at the Closing.

 

    	 

    	 

    

 

(b)
Payment. At the Closing, each Purchaser will pay to an account designated by the Company, by wire transfer of immediately available
funds, (1) the amount set forth opposite its name on Exhibit A hereto under the heading “Total Subscription Amount”
(as reduced pursuant to Section 1.1(a)(A)(iii) hereof, if applicable) (“Total Subscription Amount”), plus (2)
the product of (x) $0.125 multiplied by (y) each share of Common Stock issuable upon exercise of
the Common Warrants (without regard to any exercise limitations set forth in the Common Warrants) to be issued to such Purchaser at the
Closing. The Company will (i) instruct the Transfer Agent to credit each Purchaser the number of Common Shares purchased by the
Purchaser pursuant to Section 1.1 hereof (and, upon request, will deliver stock certificates to such Purchaser representing such Common
Shares), (ii) deliver to each Purchaser the Common Warrants purchased by such Purchaser pursuant
to Section 1.1 hereof, (iii) if applicable, issue a Pre-Funded Warrant purchased by such Purchaser pursuant to Section 1.1 hereof
and (iv) on the Closing Date (defined below) deliver written notice from the Company or the Transfer Agent evidencing the issuance to
the Purchaser of the Common Shares on and as of the Closing Date.

 

(c)
Closing Date. The Closing will take place as soon as reasonably practicable after the date hereof but no later than September 29,
2022 unless agreed to by the Company and all Purchasers (the date on which the Closing actually occurs, the “Closing Date”)
and the Closing will be held remotely via the exchange of documents and signatures, or at such other time and place as agreed upon by
the Company and the Purchasers subscribing for a majority of the Securities to be sold and issued hereunder (on a fully-diluted basis),
based on the amounts set forth on Exhibit A hereto under the heading “Common Share Subscription Amount”.

 

Article
2

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

Except
as specifically contemplated by this Agreement, the Company hereby represents and warrants to the Purchasers and the Placement Agent
as of the date of this Agreement that:

 

2.1
Good Standing of the Company; No Subsidiaries. The Company has been duly incorporated, is validly existing as a corporation in good
standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct
its business as described in the reports, schedules, forms, statements and other documents required to be filed by it with the SEC, pursuant
to the reporting requirements of the Exchange Act (all of the foregoing filed prior to the date hereof and all exhibits included therein
and financial statements and schedules thereto and documents (other than exhibits) incorporated by reference therein, the “SEC
Documents”) and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct
of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified
or be in good standing would not have a Material Adverse Effect on the Company. The Company does not have any Subsidiaries.

 

2.2
Authorization of Capital Stock. The authorized capital stock of the Company consists of 40,000,000 shares of Common Stock, $0.001
par value per share, and 2,000,000 shares of Preferred Stock, $0.001 par value per share. As of September 1, 2022, 23,368,567 shares
of Common Stock were issued and outstanding and no shares of Preferred Stock were issued and outstanding. The shares of capital stock
of the Company, including the Common Stock outstanding prior to the issuance of the Securities, have been duly authorized and are validly
issued, fully paid and non-assessable and were not issued in violation of the preemptive or similar rights of any security holder of
the Company.

 

2.3
Authorization of Shares. The Common Shares, Common Warrant Shares and Pre-Funded Warrant Shares have been duly authorized and, when
issued and delivered in accordance with the terms of this Agreement, the Common Warrants and the Pre-Funded Warrants, respectively, will
be validly issued, fully paid and non-assessable, and the issuance of such Common Shares, Common Warrant Shares and Pre-Funded Warrant
Shares will not be subject to any preemptive or similar rights of stockholders of the Company.

 

    	2

    	 

    

 

2.4
Private Placement. Neither the Company nor any of its Affiliates, nor any Person acting on its or their behalf, has, directly or
indirectly, made any offers or sales of any security or solicited any offers to buy any security, under any circumstances that would
require registration of the Securities under the Securities Act. Assuming the accuracy of the representations and warranties of the Purchasers
contained in Article 3 hereof, the issuance of the Securities are exempt from registration under the Securities Act.

 

2.5
Authorization and Execution of Transaction Documents. The execution and delivery of this Agreement and each of the other Transaction
Documents has been duly authorized by the Company. The Company has all requisite corporate power and authority to execute, deliver and
perform its obligations under this Agreement and each of the other Transaction Documents.

 

2.6
Absence of Defaults and Conflicts. Except as otherwise disclosed in the SEC Documents, the Company is not (i) in violation of its
certificate of incorporation, by-laws or similar incorporation or organizational documents or (ii) in violation or default in the performance
or observance of any obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan
or credit agreement, note, lease or other agreement or instrument to which the Company is a party or by which it may be bound, or to
which any of the property or assets of the Company is subject (collectively, “Agreements and Instruments”),
except in the case of clause (ii), for such violations and defaults that would not result in a Material Adverse Effect on the Company;
and the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated in this Agreement
and each of the other Transaction Documents, and compliance by the Company with its obligations under this Agreement and each of the
other Transaction Documents, do not and will not, whether with or without the giving of notice or passage of time or both, conflict with
or result in a breach of any of the terms and provisions of, or constitute a default or Repayment Event (as defined below) under, or
result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to, the Agreements
and Instruments, nor will such action result in any violation of the provisions of the certificate of incorporation, by-laws or similar
organizational documents of the Company or any applicable law, statute, rule, regulation, judgment, order, writ or decree of any government,
government instrumentality or court, domestic or foreign, having jurisdiction over the Company or any of its assets, properties or operations,
except in each case (other than with respect to such certificate of incorporation, by-laws or similar organizational documents of the
Company) for such conflicts, violations, breaches or defaults which would not reasonably be expected to result in a Material Adverse
Effect on the Company. As used herein, a “Repayment Event” means any event or condition which gives the holder
of any note, debenture or other evidence of indebtedness that is material to the operations or financial results of the Company (or any
person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such
indebtedness by the Company.

 

2.7
Absence of Further Requirements. No filing with, or authorization, approval, consent, license, order, registration, exemption, qualification
or decree of, any court or governmental authority or agency or any sub-division thereof is required for the performance by the Company
of its obligations hereunder, in connection with the offering, issuance or sale of the Securities under this Agreement or the consummation
of the transactions contemplated by this Agreement, except such as have been already obtained or as may be required under the Securities
Act or the rules and regulations of the SEC thereunder, state securities or blue sky laws, the rules and regulations of the Financial
Industry Regulatory Authority, Inc. (“FINRA”) or Nasdaq.

 

2.8
No Material Adverse Effect. Except as otherwise disclosed in the SEC Documents, subsequent to the respective dates as of which information
is given in the SEC Documents: (a) the Company has not sustained any material loss or material interference with its business from fire,
explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order
or decree, (b) there has not been any change in the capital stock or increase in short-term or long-term debt of the Company, other than
a change in the number of outstanding shares of Common Stock due to the issuance of shares upon the exercise or settlement of outstanding
options or restricted stock units as described in the SEC Documents, and (c) there has not occurred any Material Adverse Effect, or any
development that would result in a prospective Material Adverse Effect, in or affecting the condition, financial or otherwise, or in
or affecting the revenues, business, assets, management, financial position, stockholders’ equity, operations or results of operations
or prospects of the Company.

 

    	3

    	 

    

 

2.9
Absence of Proceedings. There are no legal or governmental proceedings, inquiries or investigations pending or, to the Company’s
knowledge, threatened to which the Company is a party or to which any of the properties of the Company is subject, other than proceedings
accurately described in all material respects in the SEC Documents or proceedings that would not have a Material Adverse Effect on the
Company, or on the power or ability of the Company to perform its obligations under this Agreement or to consummate the transactions
contemplated by this Agreement.

 

2.10
Investment Company Act of 1940. The Company is not, and after giving effect to the offering and sale of the Common Shares, Common
Warrants and Pre-Funded Warrants and the application of the proceeds thereof as described herein will not be, required to register as
an “investment company” as such term is defined in the Investment Company Act of 1940, as amended.

 

2.11
Registration Rights. Except as described in the SEC Documents, there are no contracts, agreements or understandings between the Company
and any person granting such person the right to require the Company to file a registration statement under the Securities Act with respect
to any securities of the Company or to require the Company to include such securities with the Securities registered pursuant to a Registration
Statement other than rights that have been validly waived.

 

2.12
Title to Real and Personal Property. Except as set forth in the SEC Documents, the Company has good and marketable title in fee simple
to all real property and good and marketable title to all personal property owned by it which is material to the business of the Company,
in each case free and clear of all liens, encumbrances and defects, except such as are described in the SEC Documents or such as do not
materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property
by the Company; and any real property and buildings held under lease by the Company are held by it under valid, subsisting and enforceable
leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings
by the Company.

 

2.13
Title to Intellectual Property. Except as disclosed in the SEC Documents, the Company owns, possesses, licenses or has other rights
to use all patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses,
inventions, trade secrets, technology, know-how and other intellectual property that, to the knowledge of the Company, is necessary for
the conduct of the Company’s business as now conducted (as described in the SEC Documents, collectively, the “Company
Intellectual Property”), and, to the Company’s knowledge, the patents, trademarks, and copyrights included within
the Company Intellectual Property are valid, enforceable, and subsisting. Except as set forth in the SEC Documents or except in each
case as would not reasonably be expected to have a Material Adverse Effect on the Company: (a) there are no material rights of third
parties to any such Company Intellectual Property; (b) to the Company’s knowledge, there is no material infringement by third parties
of any such Company Intellectual Property; (c) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding
or claim by others challenging the Company’s rights in or to any such Company Intellectual Property; (d) there is no pending or,
to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such
Company Intellectual Property; (e) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim
by others that the Company infringes or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights
of others; (f) to the Company’s knowledge, there is no U.S. patent which contains claims that dominate any Company Intellectual
Property described in the SEC Documents or that interferes under 35 U.S.C. §102(g) with the pending claims of any Company Intellectual
Property; (g) to the Company’s knowledge, there is no prior art of which the Company is aware that would render any U.S. patent
held by the Company invalid which has not been disclosed to the U.S. Patent and Trademark Office (the “PTO”);
and (h) the Company is not obligated to pay a material royalty, grant a license, or provide other material consideration to any third
party in connection with the Company Intellectual Property. Except as otherwise disclosed in the SEC Documents, to the Company’s
knowledge, all patents and patent applications owned by the Company and filed with the PTO or any foreign or international patent authority
(the “Company Patent Rights”) and all patents and patent applications in-licensed by the Company and filed
with the PTO or any foreign or international patent authority (the “In-licensed Patent Rights”) have been duly
and properly filed; the Company has complied with their duty of candor and disclosure to the PTO for the Company Patent Rights and, to
the Company’s knowledge, the licensors of the In-licensed Patent Rights have complied with their duty of candor and disclosure
to the PTO for the In-licensed Patent Rights.

 

    	4

    	 

    

 

2.14
Insurance. Except as set forth in the SEC Documents, the Company is insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as are prudent and customary in the business in which it is engaged; the Company has not been
refused any coverage sought or applied for; and the Company does not have any reason to believe that it will not be able to renew its
existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary
to continue its business at a cost that would not have a Material Adverse Effect on the Company.

 

2.15
Licenses and Permits. Except as set forth in the SEC Documents, the Company possesses all certificates, authorizations, consents,
approvals, orders, licenses and permits issued by the appropriate federal, state or foreign regulatory authorities (collectively, the
“Permits”), including the FDA and any other state, federal or foreign agencies or bodies engaged in the regulation
of pharmaceuticals or biohazardous materials, necessary to conduct its business as now conducted and described in the SEC Documents,
other than such certificates, authorizations, consents, approvals, orders, licenses and permits, the lack of which would not individually
or in the aggregate have a Material Adverse Effect on the Company. Except as otherwise disclosed in the SEC Documents, all of such Permits
are valid and in full force and effect, except where the invalidity of such Permits or the failure to be in full force and effect, individually
or in the aggregate, would not have a Material Adverse Effect on the Company. Except as otherwise disclosed in the SEC Documents, there
is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or investigation that individually or in the
aggregate would reasonably be expected to lead to the revocation, modification, termination, suspension or any other impairment of the
rights of the holder of any such Permit which revocation, modification, termination, suspension or other impairment would have a Material
Adverse Effect on the Company.

 

2.16
Accounting Controls. The Company has taken all actions reasonably necessary to ensure that, within the time period required by applicable
law, the Company will have established and will maintain a system of internal control over financial reporting (as such term is defined
in Rule 13a-15(f) under the Exchange Act) sufficient to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with United States generally accepted accounting principles
(“U.S. GAAP”). Except as set forth in the SEC Documents, since the end of the Company’s most recent audited
fiscal year, there has been (A) no material weakness in the Company’s internal control over financial reporting (whether or not
remediated) and (B) no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably
likely to materially affect, the Company’s internal control over financial reporting.

 

2.17
Disclosure Controls. The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the
Exchange Act) that comply with the applicable requirements of the Exchange Act; and such disclosure controls and procedures have been
designed to ensure that material information relating to the Company is made known to the Company’s principal executive officer
and principal financial officer by others within the Company. The Company has carried out evaluations of the effectiveness of its disclosure
controls and procedures as required by Rule 13a-15 of the Exchange Act.

 

    	5

    	 

    

 

2.18
Independent Accountants. EisnerAmper LLP, who have certified the financial statements and supporting schedules of the Company that
are included in the SEC Documents and which will be included as a part of the Registration Statement, is an independent registered public
accounting firm with respect to the Company as required by the Securities Act and the rules and regulations of the SEC thereunder.

 

2.19
SEC Documents. Except for the Company’s Form 8-K filed with the SEC on November 16, 2021, which was not timely filed, the Company
has timely filed the SEC Documents required to be filed by it with the SEC since May 6, 2021, pursuant to the reporting requirements
of the Exchange Act. As of their respective dates, the SEC Documents complied in all material respects with the requirements of the Exchange
Act or the Securities Act, as the case may be, and the rules and regulations of the SEC promulgated thereunder applicable to the SEC
Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact
or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading.

 

2.20
Financial Statements. (a) The financial statements included in the SEC Documents, together with the related schedules and notes,
present fairly, in all material respects, the financial position of the Company at the dates indicated and the statement of operations,
stockholders’ equity and cash flows of the Company for the periods specified; said financial statements have been prepared in conformity
with U.S. GAAP applied on a consistent basis throughout the periods involved except, in the case of unaudited interim financial statements,
for normal year-end audit adjustments and the exclusion of footnotes. The summary financial information included in the SEC Documents
present fairly, in all material respects, the information shown therein and have been compiled on a basis consistent in all material
respects with that of the audited financial statements included in the SEC Documents. (b) Except as set forth in the SEC Documents, there
are no off-balance sheet arrangements, outstanding guarantees or other contingent obligations of the Company that would reasonably be
expected to have a Material Adverse Effect on the Company. There are no transactions, arrangements or other relationships between and/or
among the Company, any of its affiliates (as such term is defined in Rule 405 of the Securities Act) and any unconsolidated entity, including,
but not limited to, any structured finance, special purpose or limited purpose entity, that would reasonably be expected to materially
affect the Company’s liquidity or the availability of or requirements for its capital resources required to be described in SEC
Documents which have not been described as required.

 

2.21
Tax Liabilities and Reserves. Other than as set forth in the SEC Documents, any tax returns required to be filed by the Company in
any jurisdiction have been filed and any taxes, including any withholding taxes, excise taxes, penalties and interest, assessments and
fees and other charges due or claimed to be due from the Company have been paid, other than any of those being contested in good faith
and for which adequate reserves have been provided or any of those currently payable without penalty or interest, except to the extent
that the failure to so file or pay would not result in a Material Adverse Effect on the Company. There is no material proposed tax deficiency,
assessment, charge or levy against the Company, as to which a reserve would be required to be established under U.S. GAAP, that has not
been so reserved or that should be disclosed in the SEC Documents that has not been so disclosed, except for any such deficiency, assessment,
charge or levy which, individually or in the aggregate, would not have a Material Adverse Effect on the Company.

 

2.22
Related Party Transactions. Except as described in the SEC Documents, no relationship, direct or indirect, exists between or among
the Company, on the one hand, and the directors, officers, stockholders, licensees, licensors or suppliers of the Company, on the other
hand, that is required to be described in the SEC Documents which is not so described. There are no outstanding loans, advances (except
normal advances for business expense in the ordinary course of business) or guarantees of indebtedness by the Company, to or for the
benefit of any of the officers or directors of the Company or any of their respective family members, except as otherwise disclosed in
the SEC Documents.

 

    	6

    	 

    

 

2.23
Commission Agreements. The Company is not a party to any contract, agreement or understanding with any person that would give rise
to a valid claim against the Company or the Placement Agent for a brokerage commission, finder’s fee or like payment in connection
with any transaction contemplated by this Agreement, except for dealings with the Placement Agent, whose commissions and fees will be
paid by the Company.

 

2.24
Foreign Corrupt Practices Act. Neither the Company nor, to the Company’s knowledge, any of its affiliates, directors, officers,
employees, agents or other person acting on behalf of the Company is aware of or has taken any action, directly or indirectly, that would
result in a material violation by such person of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations
thereunder (the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality
of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of money, or other
property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term
is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention
of the FCPA and the Company and, to the Company’s knowledge, its affiliates have conducted their businesses in material compliance
with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue
to ensure, continued compliance therewith.

 

2.25
Use of Proceeds. The Company shall use the net proceeds of the sale of the Common Shares, Common Warrants and Pre-Funded Warrants
hereunder for non-clinical and clinical development activities for its product candidates and general corporate purposes.

 

2.26
Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm’s length purchaser with respect to this Agreement and the transactions contemplated
hereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity with respect to the Company) with respect to this Agreement and the transactions contemplated hereby and any advice given by
any Purchaser or any of their respective representatives or agents to the Company in connection with this Agreement and the transactions
contemplated hereby is merely incidental to such Purchaser’s purchase of the Securities. The Company further represents to each
Purchaser that the Company’s decision to enter into this Agreement has been based on the independent evaluation of the transactions
contemplated hereby by the Company and its representatives.

 

2.27
No Reliance. The Company has not relied upon the Placement Agent or legal counsel for the Placement Agent for any legal, tax or accounting
advice in connection with the offering and sale of the Securities.

 

2.28
No Manipulation of Stock. The Company has not taken, directly or indirectly, any action designed to stabilize or manipulate the price
of the Common Stock or any security of the Company to facilitate the sale or resale of any of the Securities.

 

2.29
Never a Shell Company. The Company has never been an issuer subject to Rule 144(i) under the Securities Act.

 

2.30
The Nasdaq Capital Market. The Common Stock is listed on The Nasdaq Capital Market, and to the Company’s knowledge, there are
no proceedings to revoke or suspend such listing. The Company is in material compliance with the requirements of Nasdaq for continued
listing of the Common Stock thereon and any other Nasdaq listing and maintenance requirements.

 

    	7

    	 

    

 

Any
certificate signed by an authorized officer of the Company and required to be delivered to the Placement Agent or to counsel for the
Placement Agent in connection with this Agreement shall be deemed to be a representation and warranty by the Company to the Placement
Agent as to the matters set forth therein.

 

Article
3

PURCHASER’S REPRESENTATIONS AND WARRANTIES

 

Each
Purchaser represents and warrants to the Company and the Placement Agent, severally and not jointly, with respect to itself and its purchase
hereunder, that as of the Closing:

 

3.1
Investment Purpose. The Purchaser is purchasing the Securities for its own account and not with a present view toward the public
sale or distribution thereof and has no intention of selling or distributing any of such Securities or any arrangement or understanding
with any other Persons regarding the sale or distribution of such Securities except in accordance with the provisions of Article 6 and
except as would not result in a violation of the Securities Act. The Purchaser will not, directly or indirectly, offer, sell, pledge,
transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the Securities
except in accordance with the provisions of Article 6 or pursuant to and in accordance with the Securities Act.

 

3.2
Information. The Purchaser has been furnished with all relevant materials relating to the business, finances and operations of the
Company necessary to make an investment decision, and materials relating to the offer and sale of the Securities, that have been requested
by the Purchaser, including, without limitation, the SEC Documents, and the Purchaser has had the opportunity to review the SEC Documents.
The Purchaser has been afforded the opportunity to ask questions of the Company. Neither such inquiries nor any other investigation conducted
by or on behalf of such Purchaser or its representatives or counsel shall modify, amend or affect such Purchaser’s right to rely
on the truth, accuracy and completeness of the SEC Documents and the Company’s representations and warranties contained in the
Agreement. The Purchaser specifically understands and acknowledges that, on the date of this Agreement and on the Closing Date, the Company
may have in its possession non-public information that could be material to the market price of the Securities. The Purchaser hereby
represents and warrants that, in entering into this Agreement and any of the other Transaction Documents to which it is a party and consummating
the transactions contemplated hereby and thereby, it does not require the disclosure of such non-public information to it by the Company
in order to make an investment in the Securities. The Purchaser also specifically acknowledges that the Company would not enter into
this Agreement or any other Transaction Documents in the absence of such Purchaser’s representations and acknowledgments set out
in this Agreement, and that this Agreement, including such representations and acknowledgments, are a fundamental inducement to the Company,
and a substantial portion of the consideration provided by such Purchaser, in this transaction, and that the Company would not enter
into this transaction but for this inducement.

 

3.3
Acknowledgement of Risk.

 

(a)
The Purchaser acknowledges and understands that its investment in the Securities involves a significant degree of risk, including,
without limitation, (i) the Company remains a development stage business with limited operating history and requires substantial funds
in addition to the proceeds from the sale of the Securities; (ii) an investment in the Company is speculative, and only Purchasers who
can afford the loss of their entire investment should consider investing in the Company and the Securities; (iii) the Purchaser may not
be able to liquidate its investment; (iv) transferability of the Securities is extremely limited; (v) in the event of a disposition of
the Securities, the Purchaser could sustain the loss of its entire investment; and (vi) the Company has not paid any dividends on its
Common Stock since inception and does not anticipate the payment of dividends in the foreseeable future. Such risks are more fully set
forth in the SEC Documents.

 

    	8

    	 

    

 

(b)
The Purchaser is able to bear the economic risk of holding the Securities for an indefinite period, and has knowledge and experience
in financial and business matters such that it is capable of evaluating the risks of the investment in the Securities.

 

(c)
The Purchaser has, in connection with the Purchaser’s decision to purchase Securities, not relied upon any representations
or other information (whether oral or written) other than as set forth in the representations and warranties of the Company contained
herein and the information disclosed in the SEC Documents, and the Purchaser has, with respect to all matters relating to this Agreement
and the offer and sale of the Securities, relied solely upon the advice of such Purchaser’s own counsel and has not relied upon
or consulted any counsel to the Placement Agent or counsel to the Company.

 

3.4
Governmental Review. The Purchaser understands that no United States federal or state agency or any other government or governmental
agency has passed upon or made any recommendation or endorsement of the Securities or an investment therein.

 

3.5
Transfer or Resale. The Purchaser understands that:

 

(a)
the Securities have not been and are not being registered under the Securities Act (other than as contemplated in Article 6) or any
applicable state securities laws and, consequently, the Purchaser may have to bear the risk of owning the Securities for an indefinite
period of time because the Securities may not be transferred unless (i) the resale of the Securities is registered pursuant to an effective
registration statement under the Securities Act, as contemplated in Article 6; (ii) the Purchaser has delivered to the Company an opinion
of counsel (in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the Securities
to be sold or transferred may be sold or transferred pursuant to an exemption from such registration; or (iii) the Securities are sold
or transferred pursuant to Rule 144;

 

(b)
any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and, if Rule 144
is not applicable, any resale of the Securities under circumstances in which the seller (or the Person through whom the sale is made)
may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with some other exemption under
the Securities Act or the rules and regulations of the SEC thereunder; and

 

(c)
except as set forth in Article 6, neither the Company nor any other Person is under any obligation to register the resale of the
Securities under the Securities Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder.

 

3.6
Legends.

 

(a)
The Purchaser understands the certificates or book entries representing the Securities will bear a restrictive legend in substantially
the following form, in addition to any other legend required by applicable state securities laws or as may be appropriate to legend any
restrictions on transfer set forth in this Agreement (and a stop-transfer order may be placed against transfer of the certificates or
book entries for such Securities):

 

THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE
OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE
OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS, OR UNLESS OFFERED, SOLD, PLEDGED, HYPOTHECATED
OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS. THE COMPANY SHALL BE ENTITLED TO
REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED TO THE EXTENT THAT SUCH OPINION IS REQUIRED
PURSUANT TO THAT CERTAIN SECURITIES PURCHASE AGREEMENT UNDER WHICH THE SECURITIES WERE ISSUED.

 

    	9

    	 

    

 

(b)
To the extent the resale of any issued Common Shares, Common Warrant Shares or Pre-Funded Warrant Shares is registered under the
Securities Act pursuant to an effective Registration Statement, the Company agrees to promptly (i) authorize the removal of the legend
set forth in Section 3.6(a) and any other legend not required by applicable law from such Common Shares, Common Warrant Shares or Pre-Funded
Warrant Shares, (ii) cause the Transfer Agent to issue such Common Shares, Common Warrant Shares or Pre-Funded Warrant Shares without
such legends to the holders thereof by electronic delivery at the applicable balance account at the Depository Trust Company upon surrender
of any stock certificates evidencing such Common Shares, Common Warrant Shares or Pre-Funded Warrant Shares and (iii) if required by
the Transfer Agent, cause its counsel to issue a legal opinion to effect the removal of any restrictive legends. The Company’s
obligation to remove legends under this Section 6(b) may be conditioned upon the Purchaser providing such representations and documentation
as the Company or its legal counsel deems reasonably necessary in connection with the removal of restrictive legends, provided that the
Company agrees to notify the Purchaser of any such necessary representations or documentation as soon as reasonably practicable (which
shall generally be within one Business Day following a request by a Purchaser). With respect to any Common Shares, Common Warrant Shares
or Pre-Funded Warrant Shares for which restrictive legends are removed pursuant to this Section 3.6(b), the holder thereof agrees to
only sell such Common Shares, Common Warrant Shares or Pre-Funded Warrant Shares when and as permitted by the effective Registration
Statement covering such resale and in accordance with applicable securities laws and regulations, or in accordance with Rule 144.

 

(c)
The Purchaser may request that the Company remove, and the Company agrees to authorize the removal of any legend from any Common
Shares, Common Warrant Shares or Pre-Funded Warrant Shares issued to such Purchaser (i) following any sale, or certification by a Purchaser
of the expected sale, of such Common Shares, Common Warrant Shares or Pre-Funded Warrant Shares pursuant to Rule 144, or (ii) if such
Common Shares, Common Warrant Shares or Pre-Funded Warrant Shares are eligible for sale under Rule 144 following the expiration of the
one-year holding requirement under subparagraphs (b)(1)(i) and (d) thereof and the Purchaser is not an affiliate of the Company, in each
case following receipt from the Purchaser of an appropriate certification to such effect. Following the time a legend is no longer required
for the Common Shares, Common Warrant Shares or Pre-Funded Warrant Shares under this Section 3.6(c), the Company will, no later than
two Trading Days following the delivery by a Purchaser to the Company or the Transfer Agent of a legended certificate representing such
securities (if any) and appropriate certifications that the applicable requirements have been satisfied (the “Securities
Delivery Date”), deliver or cause to be delivered to such Purchaser a certificate or evidence of book entry representing
such securities that is free from all restrictive and other legends or, in the case of Common Shares, Common Warrant Shares or Pre-Funded
Warrant Shares, if requested by Purchaser, by crediting such Common Shares, Common Warrant Shares or Pre-Funded Warrant Shares to the
account of the Purchaser or its designee with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”)
if the Company is then a participant in such system (“DWAC Delivery”); if the Company fails for any reason
to deliver Common Shares, Common Warrant Shares or Pre-Funded Warrant Shares via DWAC Delivery (if the Company is then a participant
in DWAC) to a Purchaser as required by this Section 3.6(c) (other than a failure caused by incorrect or incomplete information provided
by Purchaser to the Company), and if after such Securities Delivery Date such Purchaser is required to or otherwise purchases (in an
open market transaction or otherwise), shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of the Common Shares,
Common Warrant Shares or Pre-Funded Warrant Shares which such Purchaser was entitled to receive relating to such Securities Delivery
Date (a “Buy-In”), then the Company shall pay in cash to such Purchaser (in addition to any other remedies
available to or elected by such Purchaser) the amount by which (x) such Purchaser’s total purchase price (including any brokerage
commissions) for the shares of Common Stock so purchased exceeds (y) the product of (1) the lesser of the (a) the number of shares of
Common Stock so purchased and (b) the aggregate number of Common Shares, Common Warrant Shares or Pre-Funded Warrant Shares that such
Purchaser was entitled to receive for the Securities Delivery Date multiplied by (2) the actual sale price at which the sell order giving
rise to such purchase obligation was executed (including any brokerage commissions). For example, if a Purchaser purchases shares of
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to Common Shares, Common Warrant Shares or Pre-Funded
Warrant Shares that were not delivered via DWAC Delivery by the Securities Delivery Date with respect to which the actual sale price
(including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000, the Company shall be required to
pay such Purchaser $1,000. The Purchaser shall provide the Company written notice, within three (3) Business Days after the occurrence
of a Buy-In, indicating the amounts payable to such Purchaser in respect of such Buy-In together with applicable confirmations and other
evidence reasonably requested by the Company. Nothing herein shall limit a Purchaser’s right to pursue any other remedies available
to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Company’s failure to timely deliver the Common Shares, Common Warrant Shares or Pre-Funded Warrant Shares via DWAC Delivery
as required pursuant to the terms hereof.

 

    	10

    	 

    

 

3.7
Authorization; Enforcement. The Purchaser has the requisite power and authority to enter into this Agreement and each of the other
Transaction Documents to which the Purchaser is a party and to consummate the transactions contemplated hereby and thereby. The Purchaser
has taken all necessary action to authorize the execution, delivery and performance of this Agreement and each of the other Transaction
Documents to which the Purchaser is a party. Upon the execution and delivery of this Agreement and each of the other Transaction Documents
to which the Purchaser is a party, this Agreement and each of the other Transaction Documents to which the Purchaser is a party shall
constitute valid and binding obligations of the Purchaser enforceable in accordance with the terms hereof or thereof, except as enforceability
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting
parties’ rights generally and except as enforceability may be subject to general principles of equity and except as rights to indemnity
and contribution may be limited by state or federal securities laws or public policy underlying such laws.

 

3.8
Residency. Unless the Purchaser has otherwise notified the Company in writing, the Purchaser is a resident of the jurisdiction set
forth immediately below such Purchaser’s name on the signature pages hereto.

 

3.9
Acknowledgements Regarding Placement Agent.

 

(a)
The Purchaser acknowledges that the Placement Agent is acting as a placement agent on a “best efforts” basis for the
Securities being offered hereby and will be compensated by the Company for acting in such capacity. The Purchaser represents that (i)
the Purchaser was contacted regarding the sale of the Securities by the Placement Agent or the Company (or an authorized agent or representative
thereof) with whom the Purchaser entered into a verbal or written confidentiality agreement and (ii) no Securities were offered or sold
to it by means of any form of general solicitation or general advertising as such terms are used in Regulation D of the Securities Act.

 

(b)
The Purchaser represents that it is making this investment based on the results of its own due diligence investigation of the Company,
and has not relied on any information or advice furnished by or on behalf of the Placement Agent in connection with the transactions
contemplated hereby. The Purchaser acknowledges that the Placement Agent has not made, and will not make, any representations and warranties
with respect to the Company or the transactions contemplated hereby, and the Purchaser will not rely on any statements made by the Placement
Agent, orally or in writing, to the contrary.

 

3.10
Beneficial Ownership. As a result of the transactions contemplated by this Agreement, the Purchaser will not become both (a) the
largest beneficial owner of Common Stock and (b) a beneficial owner of more than 20% of the number of shares of Common Stock outstanding
immediately following the Closing. Beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and
the rules and regulations promulgated thereunder.

 

    	11

    	 

    

 

Article
4

COVENANTS

 

4.1
Reporting Status. The Company’s Common Stock is registered under Section 12 of the Exchange Act. During the Registration Period,
the Company will timely file all documents with the SEC, and the Company will not terminate its status as an issuer required to file
reports under the Exchange Act even if the Exchange Act or the rules and regulations thereunder would permit such termination.

 

4.2
Expenses. The Company and each Purchaser shall be liable for, and will pay, its own expenses incurred in connection with the negotiation,
preparation, execution and delivery of this Agreement and each of the other Transaction Documents to which such Person is a party, including,
without limitation, attorneys’ and consultants’ fees and expenses.

 

4.3
Financial Information. The financial statements of the Company to be included in any documents filed with the SEC will be prepared
in accordance with U.S. GAAP, consistently applied (except (i) as may be otherwise indicated in such financial statements or the notes
thereto, or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes, may be condensed or summary
statements or may conform to the SEC’s rules and instructions for Reports on Form 10-Q), and will fairly present in all material
respects the financial position of the Company and results of its operations and cash flows as of, and for the periods covered by, such
financial statements (subject, in the case of unaudited statements, to normal and recurring year-end audit adjustments).

 

4.4
Securities Laws Disclosure; Publicity. On or before the fourth business day following the date hereof, the Company shall file a Current
Report on Form 8-K with the SEC describing the terms of the transactions contemplated by this Agreement and including as an exhibit to
such Current Report on Form 8-K this Agreement, in the form required by the Exchange Act. From and after the filing of such Current Report
on Form 8-K or, if sooner, upon the Company’s issuance of a press release describing the terms of the transactions contemplated
by this Agreement, the Company represents to the Purchasers that it shall have publicly disclosed the material terms and conditions of
the transactions contemplated by this Agreement.

 

4.5
Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by this Agreement,
which shall be disclosed pursuant to Section 4.4, or information provided to a Purchaser in such Purchaser’s capacity as a director
or officer of the Company or an affiliate of such director or officer, the Company covenants and agrees that neither it, nor any other
Person acting on its behalf will provide any Purchaser or its agents or counsel with any information following the date of this Agreement
that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser
has consented to the receipt of such information and agreed with the Company to keep such information confidential. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company, provided
that the Purchaser shall remain subject to applicable law.

 

4.6
Sales by Purchasers. Each Purchaser will sell any Securities held by it in compliance with applicable prospectus delivery requirements,
if any, or otherwise in compliance with the requirements for an exemption from registration under the Securities Act and the rules and
regulations promulgated thereunder. No Purchaser will make any sale, transfer or other disposition of the Securities in violation of
federal or state securities laws.

 

4.7
Reservation of Common Stock. The Company shall reserve and keep available at all times during which the Common Warrant Shares or
Pre-Funded Warrants remain outstanding, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling
the Company to issue the Common Warrant Shares and Pre-Funded Warrant Shares pursuant to the Common Warrants and the Pre-Funded Warrants.

 

    	12

    	 

    

 

Article
5

CONDITIONS TO CLOSING

 

5.1
Conditions to Obligations of the Company. The Company’s obligation to complete the purchase and sale of the Common Shares,
Common Warrants and Pre-Funded Warrants to each Purchaser at the Closing is subject to the waiver by the Company or fulfillment as of
the Closing Date of the following conditions:

 

(a)
Receipt of Funds. The Company shall have received immediately available funds in the full amount of the Total Subscription Amount
for the Common Shares, Common Warrants and Pre-Funded Warrants being purchased in the Closing hereunder as set forth opposite such Purchaser’s
name on Exhibit A hereto, as reduced pursuant to Section 1.1 hereof (if applicable).

 

(b)
Representations and Warranties. The representations and warranties made by each Purchaser in Article 3 shall be true and correct
in all material respects as of the Closing Date.

 

(c)
Covenants. All covenants, agreements and conditions contained in this Agreement to be performed by the Purchasers on or prior to
the Closing Date shall have been performed or complied with in all material respects.

 

(d)
Blue Sky. The Company shall have obtained all necessary blue sky law permits and qualifications, or secured exemptions therefrom,
required by any state for the offer and sale of the Securities.

 

(e)
Nasdaq Qualification. The Common Shares, Common Warrant Shares and Pre-Funded Warrant Shares to be issued shall be duly authorized
for listing by Nasdaq, subject to official notice of issuance, to the extent required by the rules of Nasdaq.

 

(f)
Absence of Litigation. No proceeding challenging this Agreement or any of the other Transaction Documents or the transactions contemplated
hereby or thereby, or seeking to prohibit, alter, prevent or materially delay the Closing, shall have been instituted or be pending before
any court, arbitrator, governmental body, agency or official.

 

(g)
No Governmental Prohibition. The sale of the Securities by the Company shall not be prohibited by any law or governmental order or
regulation.

 

5.2
Conditions to Purchasers’ Obligations. Each Purchaser’s obligation to complete the purchase and sale of the Common Shares,
Common Warrants and Pre-Funded Warrants is subject to the waiver by such Purchaser or fulfillment as of the Closing Date of the following
conditions:

 

(a)
Representations and Warranties. The representations and warranties made by the Company in Article 2 shall be true and correct in
all material respects as of the Closing Date.

 

(b)
Covenants. All covenants, agreements and conditions contained in this Agreement to be performed by the Company on or prior to the
Closing Date shall have been performed or complied with in all material respects.

 

(c)
Blue Sky. The Company shall have obtained all necessary blue sky law permits and qualifications, or secured exemptions therefrom,
required by any state or foreign or other jurisdiction for the offer and sale of the Securities.

 

    	13

    	 

    

 

(d)
Nasdaq Qualification. The Common Shares, Common Warrant Shares and Pre-Funded Warrant Shares to be issued shall be duly authorized
for listing by Nasdaq, subject to official notice of issuance, to the extent required by the rules of Nasdaq.

 

(e)
No Governmental Prohibition. The sale of the Securities by the Company shall not be prohibited by any law or governmental order or
regulation

 

(f)
No Material Adverse Effect. There shall not have occurred any Material Adverse Effect, or any development that could reasonably be
expected to result in a Material Adverse Effect, as of the Closing.

 

(g)
Transfer Agent Instructions. The Company shall have delivered to the Transfer Agent irrevocable instructions to issue to such Purchaser
or in such nominee name(s) as designated by such Purchaser in writing such number of Securities set forth opposite such Purchaser’s
name on Exhibit A hereto, as adjusted pursuant to Section 1.1 hereof (if applicable).

 

Article
6

REGISTRATION RIGHTS

 

6.1
No later than November 2, 2022 (the “Filing Date”), the Company shall file a registration statement covering
the resale of the Registrable Securities with the SEC for an offering to be made on a continuous basis pursuant to Rule 415, or if Rule
415 is not available for offers and sales of the Registrable Securities, by such other means of distribution of Registrable Securities
as the Holders of a majority of such Registrable Securities may reasonably specify (the “Initial Registration Statement”).
The Initial Registration Statement shall be on Form S-3 (except if the Company is ineligible to register for resale the Registrable Securities
on Form S-3, in which case such registration shall be on Form S-1) and the Company shall effect the registration, qualifications or compliances
(including, without limitation, the execution of any required undertaking to file post-effective amendments, appropriate qualifications
or exemptions under applicable blue sky or other state securities laws and appropriate compliance with applicable securities laws, requirements
or regulations) as promptly as possible after the filing thereof, but in any event prior to the date which is five days after the receipt
of a notification of no-review in the event of no review by the SEC, or 90 days after the Filing Date in the event of a review by the
SEC. For purposes of clarification, any failure by the Company to file the Initial Registration Statement by the Filing Date or to effect
such Registration Statement within such five days after the notification of no-review or 90 days after the Filing Date, as applicable,
shall not otherwise relieve the Company of its obligations to file or effect the Initial Registration Statement as set forth above in
this Section 6.1. In the event the SEC informs the Company that all of the Registrable Securities cannot, as a result of the application
of Rule 415, be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly (i)
inform each of the Holders thereof, (ii) use its best efforts to file amendments to the Initial Registration Statement as required by
the SEC and/or (iii) withdraw the Initial Registration Statement and file a new registration statement (a “New Registration
Statement”), in either case covering the maximum number of Registrable Securities permitted to be registered by the SEC,
on Form S-3 or, if the Company is ineligible to register for resale the Registrable Securities on Form S-3, Form S-1; provided, however,
that prior to filing such amendment or New Registration Statement, the Company shall be obligated to use its best efforts to advocate
with the SEC for the registration of all of the Registrable Securities. In the event the Company amends the Initial Registration Statement
or files a New Registration Statement, as the case may be, under clauses (ii) or (iii) above, the Company will use its best efforts to
file with the SEC, within 30 days following the date allowed by the SEC, one or more registration statements on Form S-3 or, if the Company
is ineligible to register for resale the Registrable Securities on Form S-3, Form S-1, to register for resale those Registrable Securities
that were not registered for resale on the Initial Registration Statement, as amended, or the New Registration Statement (the “Remainder
Registration Statements”). If the SEC limits the number of Registrable Securities permitted to be registered on a particular
Registration Statement (and notwithstanding that the Company used diligent efforts to advocate with the SEC for the registration of all
or a greater number of Registrable Securities), any required cutback of Registrable Securities (such Registrable Securities so cut back,
the “Cut Back Securities”) shall be applied to the Holders pro rata in accordance with the number of such Registrable
Securities sought to be included in such Registration Statement by reference to the amount of Registrable Securities set forth opposite
such Holder’s name on Exhibit A, as adjusted in the case of a subsequent transfer, relative to the aggregate amount of all
Registrable Securities. In no event shall any Holder be identified as a statutory underwriter in the Registration Statement unless in
response to a comment or request from the staff of the SEC or another regulatory agency; provided, that if the SEC requests that a Holder
be identified as a statutory underwriter in the Registration Statement, such Holder will have an opportunity to withdraw from the Registration
Statement.

 

    	14

    	 

    

 

6.2
All Registration Expenses incurred in connection with any registration, qualification, exemption or compliance pursuant to Section
6.1 shall be borne by the Company. The Company shall not be responsible for any Selling Expenses.

 

6.3
The Company further agrees that, in the event that (i) the Initial Registration Statement has not been filed with the SEC by November
2, 2022, (ii) the Initial Registration Statement or the New Registration Statement, as applicable, has not been declared effective by
the SEC (a) within five days after receipt of a notification of no-review (in the event of a “no-review” by the SEC), or
(b) within 90 days after the Filing Date (in the event of a review by the SEC), or (iii) after such Registration Statement is declared
effective by the SEC, is suspended by the Company or ceases to remain continuously effective as to all Registrable Securities for which
it is required to be effective, other than, in each case, within the time period(s) permitted by Section 6.7(b) (each such event referred
to in clauses (i), (ii) and (iii), (a “Registration Default”)), for more than 20 consecutive days or more than
40 days in any period of 365 days during which the Registration Default remains uncured, the Company shall pay to each Holder 1.0% of
such Holder’s Total Subscription Amount as set forth on Exhibit A hereto, as adjusted in the case of a subsequent transfer,
of such Holder’s Registrable Securities for each 30-day period (a “Penalty Period”) (provided the payment
amount shall increase by 1.0% of such Holder’s Total Subscription Amount as set forth on Exhibit A hereto, as adjusted in
the case of a subsequent transfer, for each subsequent 30-day period following the initial 30-day period), or pro rata for any portion
thereof, during which the Registration Default remains uncured; provided, however, that if a Holder fails to provide the Company
with any information that is required to be provided in such Registration Statement with respect to such Holder as set forth herein,
then the commencement of the Penalty Period described above shall be extended until two Business Days following the date of receipt by
the Company of such required information; and provided, further, that in no event shall the Company be required hereunder to pay to any
Holder pursuant to this Agreement more than 3.0% of such Holder’s Total Subscription Amount of such Holder’s Registrable
Securities, as adjusted in the case of a subsequent transfer, in any Penalty Period and in no event shall the Company be required hereunder
to pay to any Holder pursuant to this Agreement an aggregate amount that exceeds 10.0% of the Total Subscription Amount paid by such
Holder for such Holder’s Securities, as adjusted in the case of a subsequent transfer. The Company shall deliver said cash payment
to the Holder by the fifth Business Day after the end of such Penalty Period. Notwithstanding any other provision of this Section 6.3,
no Registration Default as to the Cut Back Securities shall be deemed to have occurred until the date that is 30 days following the date
on which the SEC permits the Cut Back Securities to be registered, and the payment of any penalty pursuant to this Section 6.3 shall
be calculated to apply only to the percentage of Registrable Securities which are permitted by the SEC to be registered within the timeframes
provided for in this Agreement.

 

6.4
In the case of the registration, qualification, exemption or compliance effected by the Company pursuant to this Agreement, the Company
shall, upon reasonable request, inform each Holder as to the status of such registration, qualification, exemption and compliance. At
its expense the Company shall:

 

(a)
except for such times as the Company is permitted hereunder to suspend the use of the prospectus forming part of a Registration Statement,
use its best efforts to keep such registration, and any qualification, exemption or compliance under state securities laws which the
Company determines to obtain, continuously effective with respect to a Holder, and to keep the applicable Registration Statement free
of any material misstatements or omissions, until the earlier of the following: (i) the second anniversary of the Closing Date or (ii)
the date all Common Shares, Common Warrant Shares and Pre-Funded Warrant Shares held by or issuable to such Holder may be sold under
Rule 144 without being subject to any volume, manner of sale or publicly available information requirements. The period of time during
which the Company is required hereunder to keep a Registration Statement effective is referred to herein as the “Registration
Period.”

 

    	15

    	 

    

 

(b)
advise the Holders within two Business Days:

 

(i)
when a Registration Statement or any amendment thereto has been filed with the SEC and when such Registration Statement or any post-effective
amendment thereto has become effective;

 

(ii)
of any request by the SEC for amendments or supplements to any Registration Statement or the prospectus included therein or for additional
information;

 

(iii)
of the issuance by the SEC of any stop order suspending the effectiveness of any Registration Statement or the initiation of any
proceedings for such purpose;

 

(iv)
of the receipt by the Company of any notification with respect to the suspension of the qualification of the Registrable Securities
included therein for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and

 

(v)
of the occurrence of any event that requires the making of any changes in any Registration Statement or prospectus so that, as of
such date, the statements therein are not misleading and do not omit to state a material fact required to be stated therein or necessary
to make the statements therein (in the case of a prospectus, in the light of the circumstances under which they were made) not misleading;

 

(c)
use its commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of any Registration Statement
as soon as reasonably practicable;

 

(d)
if a Holder so requests in writing, promptly furnish to each such Holder, without charge, at least one copy of each Registration
Statement and each post-effective amendment thereto, including financial statements and schedules, and, if explicitly requested, all
exhibits in the form filed with the SEC;

 

(e)
during the Registration Period, promptly deliver to each such Holder, without charge, as many copies of each prospectus included
in a Registration Statement and any amendment or supplement thereto as such Holder may reasonably request in writing; and the Company
consents to the use, consistent with the provisions hereof, of the prospectus or any amendment or supplement thereto by each of the selling
Holders of Registrable Securities in connection with the offering and sale of the Registrable Securities covered by a prospectus or any
amendment or supplement thereto;

 

(f)
during the Registration Period, if a Holder so requests in writing, deliver to each Holder, without charge, (i) one copy of the following
documents, other than those documents available via EDGAR: (A) its annual report to its stockholders, if any (which annual report shall
contain financial statements audited in accordance with generally accepted accounting principles in the United States by a firm of certified
public accountants of recognized standing), (B) if not included in substance in its annual report to stockholders, its annual report
on Form 10-K (or similar form), (C) its definitive proxy statement with respect to its annual meeting of stockholders, (D) each of its
quarterly reports to its stockholders, and, if not included in substance in its quarterly reports to stockholders, its quarterly report
on Form 10-Q (or similar form), and (E) a copy of each full Registration Statement (the foregoing, in each case, excluding exhibits);
and (ii) if explicitly requested, all exhibits excluded by the parenthetical to the immediately preceding clause (E);

 

    	16

    	 

    

 

(g)
prior to any public offering of Registrable Securities pursuant to any Registration Statement, promptly take such actions as may
be necessary to register or qualify or obtain an exemption for offer and sale under the securities or blue sky laws of such United States
jurisdictions as any such Holders reasonably request in writing, provided that the Company shall not for any such purpose be required
to qualify generally to transact business as a foreign corporation in any jurisdiction where it is not so qualified or to consent to
general service of process in any such jurisdiction, and do any and all other acts or things reasonably necessary or advisable to enable
the offer and sale in such jurisdictions of the Registrable Securities covered by any such Registration Statement;

 

(h)
upon the occurrence of any event contemplated by Section 6.4(b)(v) above, except for such times as the Company is permitted hereunder
to suspend the use of a prospectus forming part of a Registration Statement, the Company shall use its best efforts to as soon as reasonably
practicable prepare a post-effective amendment to such Registration Statement or a supplement to the related prospectus, or file any
other required document so that, as thereafter delivered to purchasers of the Registrable Securities included therein, such prospectus
will not include any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading;

 

(i)
otherwise use its commercially reasonable efforts to comply in all material respects with all applicable rules and regulations of
the SEC which could affect the sale of the Registrable Securities;

 

(j)
use its commercially reasonable efforts to cause all Registrable Securities to be listed on each securities exchange or market, if
any, on which equity securities issued by the Company have been listed;

 

(k)
use its commercially reasonable efforts to take all other steps necessary to effect the registration of the Registrable Securities
contemplated hereby and to enable the Holders to sell Registrable Securities under Rule 144;

 

(l)
provide to each Holder and its representatives, if requested, the opportunity to conduct a reasonable inquiry of the Company’s
financial and other records during normal business hours and make available its officers, directors and employees for questions regarding
information which such Holder may reasonably request in order to fulfill any due diligence obligation on its part; and

 

(m)
permit a single counsel for the Holders selected by the Holder beneficially owning the largest number of Registrable Securities to
review any Registration Statement and all amendments and supplements thereto (other than supplements to a Registration Statement on Form
S-1 solely for the purpose of incorporating other filings with the SEC into such Registration Statement and other than an amendment to
a Registration Statement on Form S-1 for the purpose of converting such Registration Statement into a Registration Statement on Form
S-3), within two Business Days prior to the filing thereof with the SEC; provided that each Holder shall have an opportunity to
review all disclosures in which it is named prior to filing;

 

(n)
permit each Holder to review the information contemplated to be included in the Selling Stockholder’s section of any Registration
Statement relating to such Holder within two Business Days prior to the filing thereof with the SEC;

 

provided
that, in the case of clauses (l), (m) and (n) above, the Company shall not be required (A) to delay the filing of any Registration
Statement or any amendment or supplement thereto as a result of any unreasonably ongoing diligence inquiry by or on behalf of a Holder
or to incorporate any comments to any Registration Statement or any amendment or supplement thereto by or on behalf of a Holder if such
inquiry or comments would require an unreasonable delay in the filing of such Registration Statement, amendment or supplement, as the
case may be, or (B) to provide, and shall not provide, any Holder or its representatives with material, non-public information unless
such Holder agrees to receive such information and enters into a written confidentiality agreement with the Company in a form reasonably
acceptable to the Company.

 

    	17

    	 

    

 

6.5
The Holders shall have no right to take any action to restrain, enjoin or otherwise delay any registration pursuant to Section 6.1
hereof as a result of any controversy that may arise with respect to the interpretation or implementation of this Agreement.

 

6.6
(a) To the extent permitted by law, the Company shall indemnify each Holder and each Person controlling such Holder within the meaning
of Section 15 of the Securities Act, with respect to which any registration that has been effected pursuant to this Agreement, against
all claims, losses, damages and liabilities (or action in respect thereof), including any of the foregoing incurred in settlement of
any litigation, commenced or threatened (subject to Section 6.6(c) below), arising out of or based on any untrue statement of a material
fact contained in any Registration Statement, prospectus, any amendment or supplement thereof, or other document incident to any such
registration, qualification or compliance or based on any omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, in light of the circumstances in which they were made, or any violation by the
Company of any rule or regulation promulgated by the Securities Act applicable to the Company and relating to any action or inaction
required of the Company in connection with any such registration, qualification or compliance, and will reimburse each Holder and each
Person controlling such Holder, for reasonable legal and other out-of-pocket expenses reasonably incurred in connection with investigating
or defending any such claim, loss, damage, liability or action as incurred; provided that the Company will not be liable in any such
case to the extent that any untrue statement or omission is made in reliance upon and in conformity with written information furnished
to the Company by or on behalf of such Holder expressly for use in preparation of any Registration Statement, prospectus, amendment or
supplement; provided further, that the Company will not be liable in any such case where the claim, loss, damage or liability
arises out of or is related to the failure of such Holder to comply with the covenants and agreements contained in this Agreement respecting
sales of Registrable Securities.

 

(b)
Each Holder will severally, and not jointly, indemnify the Company, each of its directors and officers, and each Person who controls
the Company within the meaning of Section 15 of the Securities Act, against all claims, losses, damages and liabilities (or actions in
respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened (subject to Section
6.6(c) below), arising out of or based on any untrue statement of a material fact contained in any Registration Statement, prospectus,
or any amendment or supplement thereof, incident to any such registration, or based on any omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, in light of the circumstances in which they
were made, and will reimburse the Company, such directors and officers, and each Person controlling the Company for reasonable legal
and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action
as incurred, in each case to the extent, but only to the extent, that such untrue statement or omission is made in reliance upon and
in conformity with written information furnished to the Company by or on behalf of the Holder expressly for use in preparation of any
Registration Statement, prospectus, amendment or supplement. Notwithstanding the foregoing, a Holder’s aggregate liability pursuant
to this subsection (b) and/or subsection (d) shall be limited to the net amount actually received by the Holder from the sale of the
Registrable Securities.

 

    	18

    	 

    

 

(c)
Each party entitled to indemnification under this Section 6.6 (the “Indemnified Party”) shall give notice
to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified
Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party (at its expense)
to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who
shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably
be withheld, conditioned or delayed), and the Indemnified Party may participate in such defense at such Indemnified Party’s expense,
and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party
of its obligations under this Agreement, unless such failure is materially prejudicial to the Indemnifying Party in defending such claim
or litigation. An Indemnifying Party shall not be liable for any settlement of an action or claim effected without its written consent
(which consent will not be unreasonably withheld, conditioned or delayed) unless such settlement includes as an unconditional term thereof
the giving by the claimant or plaintiff to such Indemnified Party of a release from all lability in respect of such claim or litigation
and does not require a statement or admission of fault and culpability on the part of such Indemnified Party in connection with such
claim or litigation. No Indemnifying Party, in its defense of any such claim or litigation, shall, except with the consent of each Indemnified
Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving
by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation.

 

(d)
If the indemnification provided for in this Section 6.6 is held by a court of competent jurisdiction to be unavailable to an Indemnified
Party with respect to any loss, liability, claim, damage or expense referred to therein, then the Indemnifying Party, in lieu of indemnifying
such Indemnified Party thereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss,
liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the
one hand and of the Indemnified Party on the other in connection with the statements or omissions which resulted in such loss, liability,
claim, damage or expense as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and of
the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material
fact or the omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and
the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

 

6.7
(a) Each Holder agrees that, upon receipt of any notice from the Company of the happening of any event requiring the preparation
of a supplement or amendment to a prospectus relating to Registrable Securities so that, as thereafter delivered to the Holders, such
prospectus shall not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein not misleading, each Holder will forthwith discontinue disposition of Registrable Securities
pursuant to a Registration Statement and prospectus contemplated by Section 6.1 until its receipt of copies of the supplemented or amended
prospectus from the Company and, if so directed by the Company, each Holder shall deliver to the Company all copies, other than permanent
file copies then in such Holder’s possession, of the prospectus covering such Registrable Securities current at the time of receipt
of such notice.

 

(b)
Each Holder shall suspend, upon request of the Company, any disposition of Registrable Securities pursuant to any Registration Statement
and prospectus contemplated by Section 6.1 during no more than two periods of no more than 30 consecutive calendar days each during any
12-month period to the extent that the Board of Directors of the Company determines in good faith that the sale of Registrable Securities
under any such Registration Statement would be reasonably likely to cause a violation of the Securities Act or Exchange Act.

 

(c)
As a condition to the inclusion of its Registrable Securities, each Holder shall furnish to the Company such information regarding
such Holder and the distribution proposed by such Holder as the Company may reasonably request in writing, including completing a Registration
Statement Questionnaire in the form provided by the Company, or as shall be required in connection with any registration referred to
in this Article 6.

 

(d)
Each Holder hereby covenants with the Company (i) not to make any sale of the Registrable Securities without effectively causing
the prospectus delivery requirements under the Securities Act to be satisfied and (ii) if such Registrable Securities are to be sold
by any method or in any transaction other than (A) on a national securities exchange or in the over the counter market, (B) in privately
negotiated transactions, or (C) in a combination of such methods, to notify the Company at least five Business Days prior to the date
on which the Holder first offers to sell any such Registrable Securities.

 

    	19

    	 

    

 

(e)
At the end of the Registration Period the Holders shall discontinue sales of any Common Shares, Common Warrant Shares or Pre-Funded
Warrant Shares pursuant to any Registration Statement upon receipt of notice from the Company of its intention to remove from registration
the Common Shares, Common Warrant Shares or Pre-Funded Warrant Shares covered by any such Registration Statement which remain unsold,
and such Holders shall notify the Company of the number of Common Shares, Common Warrant Shares or Pre-Funded Warrant Shares registered
which remain unsold within one Business Day of receipt of such notice from the Company.

 

6.8
With a view to making available to the Holders the benefits of certain rules and regulations of the SEC which at any time permit
the sale of the Registrable Securities to the public without registration, so long as the Holders still own Registrable Securities, the
Company shall use its best efforts to:

 

(a)
make and keep public information available, as those terms are understood and defined in Rule 144 under the Securities Act, at all
times;

 

(b)
file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act; and

 

(c)
so long as a Holder owns any Registrable Securities, furnish to such Holder, upon any reasonable request, a written statement by
the Company as to its compliance with Rule 144 under the Securities Act, and of the Exchange Act, a copy of the most recent annual or
quarterly report of the Company, and such other reports and documents of the Company as such Holder may reasonably request in availing
itself of any rule or regulation of the SEC allowing a Holder to sell any such securities without registration.

 

6.9
The rights to cause the Company to register Registrable Securities granted to the Holders by the Company under Section 6.1 may be
assigned by a Holder in connection with a transfer by such Holder of all or a portion of its Registrable Securities, provided, however,
that such transfer must be made at least ten days prior to the Filing Date and that (i) such transfer may otherwise be effected in accordance
with applicable securities laws; (ii) such Holder gives prior written notice to the Company at least ten days prior to the Filing Date;
and (iii) such transferee agrees to comply with the terms and provisions of this Agreement, and such transfer is otherwise in compliance
with this Agreement. Except as specifically permitted by this Section 6.9, the rights of a Holder with respect to Registrable Securities
as set out herein shall not be transferable to any other Person, and any attempted transfer shall cause all rights of such Holder therein
to be forfeited.

 

6.10
From the date hereof until the time that Registration Statement(s) covering the resale of all Registrable Securities have been declared
effective by the SEC, neither the Company nor any direct or indirect subsidiary of the Company shall (i) issue, enter into any agreement
to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file with the
SEC a registration statement under the Securities Act of any of its equity securities other than a registration statement required to
be filed pursuant to this Agreement, a registration statement on Form S-8 or, in connection with an acquisition, a registration statement
on Form S-4; provided, however, that the foregoing restrictions in this Section 6.10 shall terminate upon such time as all of
the Registrable Securities (a) have been publicly sold by the Holders or (b) may be sold under Rule 144 during any 90-day period. Notwithstanding
the foregoing, the restrictions set forth in clause (i) of this Section 6.10 shall not apply with respect to any Exempt Issuance. As
used herein, “Exempt Issuance” means the issuance of (a) shares of Common Stock or options or restricted stock
units to employees, officers, directors or consultants of the Company pursuant to any stock or option plan duly adopted for such purpose,
by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors
established for such purpose for services rendered to the Company, (b) the securities issuable upon exercise of the Common Warrants and
Pre-Funded Warrants and/or securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding
on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number
of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection
with stock splits or combinations) or to extend the term of such securities, or (c) shares of Common Stock or Common Stock Equivalents
sold at a price per share of Common Stock that is equal to or greater than the Market Price.

 

    	20

    	 

    

 

6.11
The rights of any Holder under any provision of this Article 6 may be waived (either generally or in a particular instance, either
retroactively or prospectively and either for a specified period of time or indefinitely) or amended by an instrument in writing signed
by such Holder.

 

Article
7

 

DEFINITIONS

 

7.1
“Agreement” has the meaning set forth in the preamble.

 

7.2
“Affiliate” means, with respect to any Person (as defined below), any other Person controlling, controlled by
or under direct or indirect common control with such Person (for the purposes of this definition “control,”
when used with respect to any specified Person, shall mean the power to direct the management and policies of such Person, directly
or indirectly, whether through ownership of voting securities, by contract or otherwise; and the terms “controlling”
and “controlled” shall have meanings correlative to the foregoing).

 

7.3
“Attribution Parties” means, with respect to any Person, such Person’s Affiliates and any other Person whose
beneficial ownership of Common Stock would be aggregated with such Person’s for purposes of Section 13(d) or Section 16 of the
Exchange Act and the applicable regulations of the SEC, including any “group” of which such Person is a member.

 

7.4
“Beneficial Ownership Limitation” means the percentage set forth opposite such Purchaser’s name on Exhibit
A hereto under the heading “Beneficial Ownership Limitation”.

 

7.5
“Business Day” means a day Monday through Friday on which banks are generally open for business in New York City.

 

7.6
“Closing” has the meaning set forth in Section 1.1(a).

 

7.7
“Closing Date” has the meaning set forth in Section 1.1(c).

 

7.8
“Common Shares” has the meaning set forth in Recital B to this Agreement.

 

7.9
“Common Share Subscription Amount” has the meaning set forth in Section 1.1(a).

 

7.10
“Common Stock” means the common stock, par value $0.001 per share, of the Company.

 

7.11
“Common Stock Equivalents” means any options, warrants or other securities or rights convertible into or exercisable
or exchangeable for, whether directly or following conversion into or exercise or exchange for other options, warrants or other securities
or rights, shares of Common Stock, or any swap, hedge or similar agreement or arrangement that transfers in whole or in part, the economic
risk of ownership of, or voting or other rights of, shares of Common Stock.

 

    	21

    	 

    

 

7.12
“Common Warrants” means the Common Stock purchase warrants delivered to the Purchasers at the Closing, in the
form of Exhibit C attached hereto.

 

7.13
“Common Warrant Shares” means the shares of Common Stock issuable upon exercise of the Common Warrants.

 

7.14
“Company Intellectual Property” has the meaning set forth in Section 2.13.

 

7.15
“Cut Back Securities” has the meaning set forth in Section 6.1.

 

7.16
“Engagement Letter” means the Engagement Letter by and between the Company and the Placement Agent, dated July
1, 2022.

 

7.17
“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

7.18
“FDA” means the United States Food and Drug Administration.

 

7.19
“Filing Date” has the meaning set forth in Section 6.1.

 

7.20
“Financial Statements” means the financial statements of the Company included in the SEC Documents.

 

7.21
“Holders” means any Person holding Registrable Securities or any Person to whom the rights under Article 6 have
been transferred in accordance with Section 6.9 hereof.

 

7.22
“Indemnified Party” has the meaning set forth in Section 6.6(c).

 

7.23
“Indemnifying Party” has the meaning set forth in Section 6.6(c).

 

7.24
“Initial Registration Statement” has the meaning set forth in Section 6.1.

 

7.25
“Market Price” means $2.81.

 

7.26
“Material Adverse Effect” means a material adverse effect on (a) the business, operations, assets or condition
(financial or otherwise) of the Company, taken as a whole, or (b) the ability of the Company to perform its obligations pursuant to the
transactions contemplated by this Agreement.

 

7.27
“Nasdaq” means The Nasdaq Stock Market LLC.

 

7.28
“New Registration Statement” has the meaning set forth in Section 6.1.

 

7.29
“Penalty Period” has the meaning set forth in Section 6.3.

 

7.30
“Person” means any person, individual, corporation, limited liability company, partnership, trust or other nongovernmental
entity or any governmental agency, court, authority or other body (whether foreign, federal, state, local or otherwise).

 

7.31
“Placement Agent” means MTS Securities, LLC.

 

7.32
“Preferred Stock” means the preferred stock, par value $0.001 per share, of the Company.

 

    	22

    	 

    

 

7.33
“Pre-Funded Warrants” means the pre-funded Common Stock purchase warrants delivered to the Purchasers at the Closing,
in the form of Exhibit B attached hereto.

 

7.34
“Pre-Funded Warrant Shares” means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.

 

7.35
“Purchasers” has the meaning set forth in the preamble.

 

7.36
The terms “register,” “registered” and “registration” refer to the
registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or
ordering of the effectiveness of such registration statement.

 

7.37
“Registrable Securities” means (i) the Common Shares, (ii) the Common Warrant Shares and (iii) the Pre-Funded
Warrant Shares; provided, however, that Common Shares, Common Warrant Shares and Pre-Funded Warrant Shares shall only be treated
as Registrable Securities if and only for so long as they (A) have not been disposed of pursuant to a registration statement declared
effective by the SEC, (B) have not been sold in a transaction exempt from the registration and prospectus delivery requirements of the
Securities Act so that all transfer restrictions and restrictive legends with respect thereto are removed upon the consummation of such
sale or (C) are held by a Holder or a permitted transferee pursuant to Section 6.9.

 

7.38
“Registration Default” has the meaning set forth in Section 6.3.

 

7.39
“Registration Expenses” means all expenses incurred by the Company in complying with Section 6.1 hereof, including,
without limitation, all registration, qualification and filing fees, printing expenses, escrow fees, fees and expenses of counsel for
the Company, blue sky fees and expenses and the expense of any special audits incident to or required by any such registration (but excluding
the fees of legal counsel for any Holder).

 

7.40
“Registration Statement” means any one or more registration statements of the Company filed under the Securities
Act that covers the resale of any of the Registrable Securities pursuant to the provisions of this Agreement (including without limitation
any Initial Registration Statement, any New Registration Statement and any Remainder Registration Statements) and amendments and supplements
to such Registration Statements, including post-effective amendments.

 

7.41
“Registration Period” has the meaning set forth in Section 6.4(a).

 

7.42
“Remainder Registration Statement” has the meaning set forth in Section 6.1.

 

7.43
“Rule 144” means Rule 144 promulgated under the Securities Act, or any successor rule.

 

7.44
“Rule 415” means Rule 415 promulgated under the Securities Act, or any successor rule.

 

7.45
“SEC” means the United States Securities and Exchange Commission.

 

7.46
“SEC Documents” has the meaning set forth in Section 2.1.

 

7.47
“Securities” means, collectively, the Common Shares, the Common Warrants, the Common Warrant Shares, the Pre-Funded
Warrants and the Pre-Funded Warrant Shares.

 

7.48
“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any
similar successor statute.

 

    	23

    	 

    

 

7.49
“Selling Expenses” means all selling commissions applicable to the sale of Registrable Securities and all fees
and expenses of legal counsel for any Holder.

 

7.50
“Subsidiary” means any consolidated subsidiary of the Company as set forth in the Financial Statements.

 

7.51
“Total Subscription Amount” has the meaning set forth in Section 1.1(b).

 

7.52
“Trading Day” means a day on which the principal Trading Market is open for trading.

 

7.53
“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted
for trading on the date in question: the NYSE American, Nasdaq, or the New York Stock Exchange (or any successors to any of the foregoing).

 

7.54
“Transaction Documents” means this Agreement, the Common Warrants, the Pre-Funded Warrants, all exhibits and schedules
hereto and thereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.

 

7.55
“Transfer Agent” means Continental Stock Transfer & Trust Company, and any successor transfer agent of the
Company. 

 

Article
8

GOVERNING LAW; MISCELLANEOUS

 

8.1
Governing Law; Jurisdiction. This Agreement will be governed by and interpreted in accordance with the laws of the State of New York
without regard to the principles of conflict of laws (whether of the State of New York or any other jurisdiction) which would result
in the application of the laws of any other jurisdiction.

 

8.2
Counterparts; Signatures by Facsimile. This Agreement may be executed in counterparts, all of which are considered one and the same
agreement and will become effective when counterparts have been signed by each party and delivered to the other parties. This Agreement
may also be executed and delivered by facsimile signature, PDF or any electronic signature complying with the U.S. federal ESIGN Act
of 2000 (e.g., www.docusign.com).

 

8.3
Headings. The headings of this Agreement are for convenience of reference only, are not part of this Agreement and do not affect
its interpretation.

 

8.4
Severability. If any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such
provision will be deemed modified in order to conform with such statute or rule of law. Any provision hereof that may prove invalid or
unenforceable under any law will not affect the validity or enforceability of any other provision hereof.

 

8.5
Entire Agreement; Amendments. This Agreement (including all schedules and exhibits hereto) constitutes the entire agreement among
the parties hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties or undertakings,
other than those set forth or referred to herein or therein. This Agreement supersedes all prior agreements and understandings among
the parties hereto with respect to the subject matter hereof. No provision of this Agreement may be waived or amended other than by an
instrument in writing signed by the party to be charged with enforcement. Any amendment or waiver by a party effected in accordance with
this Section 8.5 shall be binding upon such party, including with respect to any Securities purchased under this Agreement at the time
outstanding and held by such party (including securities into which such Securities are convertible and for which such Securities are
exercisable) and each future holder of all such securities.

 

    	24

    	 

    

 

8.6
Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal
delivery to the party to be notified, (b) when sent by email or facsimile if sent during normal business hours of the recipient, and
if sent at a time other than during normal business hours of the recipient, then on the next Business Day (provided, with respect to
notices sent by email so long as such sent email is kept on file by the sending party and the sending party does not receive an automatically
generated message from the recipient’s email server that such email could not be delivered to such recipient), (c) five days after
having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one Business Day after deposit with
a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. The addresses for such
communications are:

 

	 	If
    to the Company:	Anebulo
    Pharmaceuticals, Inc.
	 	 	1415
    Ranch Road 620 South, Suite 201
	 	 	Austin,
    TX 78734
	 	 	Attn:
    Rex Merchant
	 	 	Email:
    rex@anebulo.com

 

	 	With
    a copy to:	Cooley
    LLP
	 	 	10265
    Science Center Drive
	 	 	San
    Diego, CA 92121
	 	 	Attn:
    Kenneth J. Rollins
	 	 	Email:
    krollins@cooley.com

 

If
to a Purchaser: To the address set forth immediately below such Purchaser’s name on the signature pages hereto. Each party will
provide ten days’ advance written notice to the other parties of any change in its address.

 

8.7
Successors and Assigns. This Agreement is binding upon and inures to the benefit of the parties and their successors and assigns.
The Company will not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Purchasers,
and no Purchaser may assign this Agreement or any rights or obligations hereunder without the prior written consent of the Company, except
as permitted in accordance with Section 6.9 hereof.

 

8.8
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto, their respective permitted successors
and assigns, the Persons referenced in Sections 6.6(a) and 6.6(b), and the Placement Agent, and is not for the benefit of, nor may any
provision hereof be enforced by, any other Person.

 

8.9
Further Assurances. Each party will do and perform, or cause to be done and performed, all such further acts and things, and will
execute and deliver all other agreements, certificates, instruments and documents, as another party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

8.10
No Strict Construction. The language used in this Agreement is deemed to be the language chosen by the parties to express their mutual
intent, and no rules of strict construction will be applied against any party.

 

8.11
Equitable Relief. The Company recognizes that, if it fails to perform or discharge any of its obligations under this Agreement, any
remedy at law may prove to be inadequate relief to the Purchasers. The Company therefore agrees that the Purchasers are entitled to seek
temporary and permanent injunctive relief in any such case. Each Purchaser also recognizes that, if it fails to perform or discharge
any of its obligations under this Agreement, any remedy at law may prove to be inadequate relief to the Company. Each Purchaser therefore
agrees that the Company is entitled to seek temporary and permanent injunctive relief in any such case.

 

    	25

    	 

    

 

8.12
Survival of Representations and Warranties. Notwithstanding any investigation made by any party to this Agreement, all representations
and warranties made by the Company and the Purchasers herein shall survive for a period of one year following the date hereof.

 

8.13
Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under this Agreement are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the
obligations of any other Purchaser under this Agreement. Nothing contained herein and no action taken by any Purchaser pursuant thereto,
shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create
a presumption that the Purchasers are in any way acting in concert or as a group, or are deemed affiliates with respect to such obligations
or the transactions contemplated by this Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights,
including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Purchaser to be joined
as an additional party in any proceeding for such purpose. The Company has elected to provide all Purchasers with the same terms of this
Agreement for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly
understood and agreed that each provision contained in this Agreement is between the Company and a Purchaser, solely, and not between
the Company and the Purchasers collectively and not between and among the Purchasers. Notwithstanding anything to the contrary in the
foregoing, each of the Purchasers has been advised, and is being advised by this Agreement, to consult with an attorney before executing
this Agreement, and each Purchaser has consulted (or had an opportunity to consult) with counsel of such Purchaser’s choice concerning
the terms and conditions of this Agreement for a reasonable period of time prior to the execution hereof and thereof.

 

8.14
Exculpation of the Placement Agent. Each party hereto agrees for the express benefit of the Placement Agent and its Affiliates and
representatives that:

 

(a)
The Placement Agent and its Affiliates and representatives (i) have no duties or obligations other than those specifically set forth
herein or in the Engagement Letter; (ii) shall not be liable for any improper payment made in accordance with the information provided
by the Company; (iii) make no representation or warranty, and have no responsibilities as to the validity, accuracy, value or genuineness
of any information, certificates or documentation delivered by or on behalf of the Company pursuant to this Agreement or in connection
with any of the transactions contemplated hereby; and (iv) shall not be liable (A) for any action taken, suffered or omitted by any of
them in good faith and reasonably believed to be authorized or within the discretion or rights or powers conferred upon them by this
Agreement, or (B) for anything which any of them may do or refrain from doing in connection with this Agreement, except in each case
for such Person’s own gross negligence, willful misconduct or bad faith.

 

(b)
The Placement Agent and its Affiliates and representatives shall be entitled to (i) rely on, and shall be protected in acting upon,
any certificate, instrument, notice, letter or any other document or security delivered to any of them by or on behalf of the Company,
and (ii) be indemnified by the Company for acting as a Placement Agent hereunder pursuant to the indemnification provisions set forth
in the Engagement Letter.

 

8.15
Waiver of Conflicts. Each Purchaser acknowledges that Cooley LLP, outside legal counsel to the Company, may have in the past performed
and may now or in the future represent one or more Purchasers or their Affiliates in matters unrelated to the transactions contemplated
by this Agreement (the “Financing”), including representation of such Purchasers or their Affiliates in matters
of a similar nature to the Financing. The applicable rules of professional conduct require that Cooley LLP inform the Purchasers hereunder
of this representation and obtain their consent. Cooley LLP has served as outside legal counsel to the Company and has negotiated the
terms of the Financing solely on behalf of the Company. Each Purchaser hereby (a) acknowledges that they have had an opportunity to ask
for and have obtained information relevant to such representation, including disclosure of the reasonably foreseeable adverse consequences
of such representation; (b) acknowledges that with respect to the Financing, Cooley LLP has represented solely the Company, and not any
Purchaser or any stockholder, director or employee of the Company or any Purchaser; and (c) gives its informed consent to Cooley LLP’s
representation of the Company in the Financing.

 

[Signature
Pages Follow]

 

    	26

    	 

    

 

IN
WITNESS WHEREOF, the undersigned has caused this Securities Purchase Agreement to be duly executed as of the date first above written.

 

	Anebulo
    Pharmaceuticals, Inc.	 
	 	 	 
	By:	/s/
    Simon Allen 	 
	Name:	Simon
    Allen	 
	Title:	Chief
    Executive Officer	 

 

[Signature
Page to Securities Purchase Agreement]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the undersigned has caused this Securities Purchase Agreement to be duly executed as of the date first above written.

 

	Purchaser:	 
	 	 	 
	22NW
    Fund, LP	 
	 	 	 
	By:	/s/
    Aron English	 
	Name:	Aron
    English	 
	Title:	President	 

 

[Signature
Page to Securities Purchase Agreement]

 

    	 

    	 

    

 

 

IN
WITNESS WHEREOF, the undersigned has caused this Securities Purchase Agreement to be duly executed as of the date first above written.

 

	Purchaser:	 
	 	 	 
	Nantahala
    Capital Partners Limited Partnership	 
	 	 	 
	By:	Nantahala
Capital Management, LLC	 
	 	Its
    General Partner	 
	 	 	 
	By:	/s/
    Daniel Mack	 
	Name:	Daniel
    Mack	 
	Title:	Manager	 

 

[Signature
Page to Securities Purchase Agreement]

 

    	 

    	 

    

 

 

IN
WITNESS WHEREOF, the undersigned has caused this Securities Purchase Agreement to be duly executed as of the date first above written.

 

	Purchaser:	 
	 	 	 
	NCP RFM LP	 
	 	 	 
	By:	Nantahala
Capital Management, LLC	 
	 	Its
    Investment Manager	 
	 	 	 
	By:	/s/
    Daniel Mack	 
	Name:	Daniel
    Mack	 
	Title:	Manager	 

 

[Signature
Page to Securities Purchase Agreement]

 

    	 

    	 

    

 

 

IN
WITNESS WHEREOF, the undersigned has caused this Securities Purchase Agreement to be duly executed as of the date first above written.

 

Purchaser:

 

Blackwell
Partners LLC – Series A,

solely
with respect to the portion of its

assets
for which Nantahala Capital Management, LLC

acts
as its Investment Manager

 

	By:	Nantahala
    Capital Management, LLC	 
	 	Its
    Investment Manager	 
	 	 	 
	By:	/s/
    Daniel Mack	 
	Name:	 Daniel
    Mack	 
	Title:	Manager	 

 

[Signature
Page to Securities Purchase Agreement]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the undersigned has caused this Securities Purchase Agreement to be duly executed as of the date first above written.

 

	Purchaser:	 
	 	 	 
	ADAR1 Partners, LP	 
	 	 	 
	By:	/s/
    Daniel Schneeberger	 
	Name:	Daniel
    Schneeberger	 
	Title:	Managing
    Member of the General Partner	 

 

[Signature
Page to Securities Purchase Agreement]

 

    	 

    	 

    

 

EXHIBIT
A

 

SCHEDULE
OF PURCHASERS

 

	Purchaser	 	Beneficial

                                                                                Ownership

                                                                                Limitation
	 	 	Common Share

                                                                                Subscription

                                                                                Amount
	 	 	Common

                                                                                Warrant

                                                                                Subscription

                                                                                Amount
	 	 	Total

                                                                                Subscription

                                                                                Amount
	 
	22 NW Fund, LP	 	 	12,000,000 shares	 	 	$	4,787,051.37	 	 	$	212,947.13	 	 	$	4,999,998.50	 
	Nantahala Capital Partners Limited Partnership	 	 	9.99	%	 	$	252,635.86	 	 	$	11,238.25	 	 	$	263,874.11	 
	NCP RFM LP	 	 	9.99	%	 	$	333,010.29	 	 	$	14,813.63	 	 	$	347,823.92	 
	Blackwell Partners LLC – Series A	 	 	9.99	%	 	 	850,468.98	 	 	 	37,832.25	 	 	$	888,301.23	 
	ADAR1 Partners, LP	 	 	4.99	%	 	$	140,500.00	 	 	$	6,250.00	 	 	$	146,750.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total:	 	 	 	 	 	$	6,363,666.50	 	 	$	283,081.26	 	 	$	6,646,747.76Exhibit 4.2

 

THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE
OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE
OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS, OR UNLESS OFFERED, SOLD, PLEDGED, HYPOTHECATED
OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS. THE COMPANY SHALL BE ENTITLED TO
REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED TO THE EXTENT THAT SUCH OPINION IS REQUIRED
PURSUANT TO THAT CERTAIN SECURITIES PURCHASE AGREEMENT UNDER WHICH THE SECURITIES WERE ISSUED.

 

COMMON
STOCK PURCHASE WARRANT

 

ANEBULO
PHARMACEUTICALS, INC.

 

	Warrant
    Shares: [●]	Issue
    Date: September 28, 2022
	 	 
	 	Initial
    Exercise Date: September 28, 2022

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●] or its assigns (the
“Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m.
(New York City time) on September 28, 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase
from Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to [•] shares (as subject to adjustment
hereunder, the “Warrant Shares”) of the Company’s Common Stock, par value $0.001 per share (the “Common
Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b).

 

Section
1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the “Purchase Agreement”), dated September 25, 2022, among the Company and the purchasers
signatory thereto.

 

    	1

    	 

    

 

Section
2. Exercise.

 

(a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile
copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as Exhibit A
(the “Notice of Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising
the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s
check drawn on a United States bank. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder
shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available
hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation
within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this
Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering
the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.
The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The
Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. The Holder and
any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the
purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time
may be less than the amount stated on the face hereof.

 

(b)
Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $4.215, subject to adjustment hereunder
(the “Exercise Price”).

 

(c)
[Reserved].

 

(d)
Mechanics of Exercise.

 

(i)
Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant
in such system and there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by the Holder, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name
of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address
specified by the Holder in the Notice of Exercise by the date that is the earlier of (A) the earlier of (i) two (2) Trading Days and
(ii) the number of days comprising the Standard Settlement Period, in each case after the delivery to the Company of the Notice of Exercise
and (B) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company (such date, the “Warrant Share Delivery
Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price is received by the Warrant Share Delivery Date. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company
shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per
Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date
until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant
in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period”
means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

 

    	2

    	 

    

 

(ii)
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.

 

(iii)
Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

(iv)
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence, the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

    	3

    	 

    

 

(v)
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.

 

(vi)
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto as Exhibit B (the “Assignment Form”)
duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for
any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of
Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required
for same-day electronic delivery of the Warrant Shares.

 

    	4

    	 

    

 

(vii)
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

(e)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Attribution Parties),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the number of shares of Common
Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of
shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially
owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any
other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion
or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Attribution Parties. Except as
set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company
is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely
responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section
2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and
the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination; provided, however, if the Company determines that any attempted exercise of this Warrant would result in the Holder
owning in excess of [For Outside Investors: 19.99% of the outstanding Common Stock immediately following such exercise][For
22NW Fund, LP: the Beneficial Ownership Limitation] (any such shares in excess of such limit,
the “Excess Shares”), then the Company shall not be obligated to issue
to the Holder any such Excess Shares. In addition, a determination as to any group status as contemplated above shall be determined
in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section
2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common
Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the SEC, as the case may be, (B) a more
recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the
number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading
Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including
this Warrant, by the Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was
reported. The “Beneficial Ownership Limitation” shall be [For Outside Investors: [4.99/9.99]% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise
of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 19.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder
and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective
until the 61st day after such notice is delivered to the Company.] [For 22NW Fund, LP: 12,000,000 shares of Common
Stock (as adjusted for any stock splits or combinations following the date of the Purchase Agreement), which number is fewer than the
number of shares representing the largest beneficial ownership position in the Common Stock as of immediately before, and immediately
after, the date of the Purchase Agreement (provided, however, this Beneficial Ownership Limitation shall be (i) immediately removed if
and when the stockholders of the Company approve the removal of such Beneficial Ownership Limitation in accordance with Nasdaq Listing
Rule 5635(b) (or any successor thereof) or (ii) immediately increased or removed, as applicable, to the extent that such increase or
removal would not result in a change of control under Nasdaq Listing Rule 5635(b) (or any successor thereof)).] The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.

 

    	5

    	 

    

 

Section
3. Certain Adjustments.

 

(a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.

 

(b)
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that to the
extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

(c)
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided,
however, that to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).

 

    	6

    	 

    

 

(d)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of
its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other
disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase
offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock
are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of
50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any
reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common
Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock
held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to,
such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon
any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to
any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor
entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in
writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions
of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder
(not to be unreasonably withheld, conditioned or delayed) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the
other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.

 

    	7

    	 

    

 

(e)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

(f)
Notice to Holder.

 

(i)
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

(ii)
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at
its last facsimile number or email address as it shall appear upon the Warrant Register (as defined below), at least 20 calendar days
prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken
for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which
the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares
of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer
or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect
the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant
constitutes, or contains, material, non-public information regarding the Company or any of its Subsidiaries, the Company shall simultaneously
file such notice with the SEC pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during
the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be
expressly set forth herein.

 

Section
4. Transfer of Warrant.

 

(a)
Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with the
Assignment Form duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the
making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such Assignment Form,
and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly
be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company
within three (3) Trading Days of the date on which the Holder delivers the Assignment Form to the Company assigning this Warrant in full.
The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without
having a new Warrant issued.

 

    	8

    	 

    

 

(b)
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant
and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

(c)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
“Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.

 

Section
5. Miscellaneous.

 

(a)
No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting the rights of a Holder to receive the cash payments contemplated pursuant to Sections 2(d)(i),
2(d)(iv) and 2(d)(v), in no event will the Company be required to net cash settle an exercise of this Warrant.

 

(b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.

 

(c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading
Day.

 

    	9

    	 

    

 

(d)
Authorized Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.

 

(e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
in accordance with the provisions of the Purchase Agreement.

 

    	10

    	 

    

 

(f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will
have restrictions upon resale imposed by state and federal securities laws.

 

(g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding the fact that
the right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant or the Purchase
Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any
amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

(h)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered in accordance with the notice provisions of the Purchase Agreement.

 

(i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.

 

(j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.

 

(k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.

 

(l)
Entire Agreement; Amendment. This Warrant and each of the other Transaction Documents constitutes the entire agreement among the
parties hereto with respect to the subject matter hereof and thereof. This Warrant and each of the other Transaction Documents supersedes
all prior agreements and understandings among the parties hereto with respect to the subject matter hereof and thereof. This Warrant
may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of
this Warrant, on the other hand.

 

(m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.

 

(n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.

 

********************

 

(Signature
Page Follows)

 

    	11

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.

 

	 	ANEBULO
    PHARMACEUTICALS, Inc.
	 	 
	 	By:	                               
	 	Name:	Simon
    Allen
	 	Title:
    	Chief
    Executive Officer

 

    	12

    	 

    

 

EXHIBIT
A

 

NOTICE
OF EXERCISE

 

To:
ANEBULO PHARMACEUTICALS, Inc.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)
Payment shall take the form of lawful money of the United States.

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: ________________________________________________________________________

Signature
of Authorized Signatory of Investing Entity: _________________________________________________

Name
of Authorized Signatory: ___________________________________________________________________

Title
of Authorized Signatory: ____________________________________________________________________

Date:
________________________________________________________________________________________

 

    	 

     

    

 

EXHIBIT
B

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase
shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 
	 	(Please
    Print)
	 	 
	Address:	 
	 	(Please
    Print)
	 	 
	Phone
    Number:	 
	 	 
	Email
    Address: 	 
	 	 
	Dated:
____________________, _______	 
	 	 
	Holder’s
Signature: ________________________________	 
	 	 
	Holder’s
    Address: _________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]